Introduction

Traveling abroad for serious medical treatment can feel overwhelming because the path is often unclear. Patients and families may wonder who reviews the case, how hospitals are selected, how pricing works, whether visas are supported, what happens after arrival, and who follows up after discharge.

The ChinaCureLink process is designed to make medical treatment in China more structured, transparent, and manageable for international patients.

Most patients move from first inquiry to treatment start in about 3–6 weeks, depending on medical complexity, record readiness, hospital review time, visa requirements, and travel planning.

This guide explains each step clearly, from free remote case review to follow-up after returning home.

At a Glance — The 7-Step Timeline

Step	What Happens	Who Handles It	Typical Duration
1	Free remote case review	Patient + ChinaCureLink medical coordination team	Days 1–5
2	Hospital and specialist matching	ChinaCureLink + hospital partners	Days 5–10
3	Treatment plan and quote	Hospital team + coordinator	Days 10–14
4	Visa, travel and arrival logistics	ChinaCureLink + patient family	1–3 weeks
5	Admission and treatment phase	Hospital team + bilingual coordinator	Varies by treatment
6	Discharge and recovery in China	Hospital + coordinator	Days to weeks
7	Follow-up after return home	ChinaCureLink + home physician	Ongoing

Step 1 — Free Remote Case Review

The first step is a free remote case review. This helps patients understand whether treatment in China may be medically reasonable before they spend money on travel.

What to Submit

Patients are usually asked to submit medical records, diagnosis reports, imaging, pathology reports if relevant, lab results, prior treatment history, medication list, discharge summaries, and current doctor recommendations.

For cancer cases, this may include PET/CT, MRI, biopsy report, genetic testing, chemotherapy history, immunotherapy history, or CAR-T eligibility documents.

For kidney disease, this may include creatinine, eGFR, urine protein, dialysis records, kidney imaging, and nephrology notes.

Who Reviews It

The case is reviewed by medically trained coordinators and relevant hospital specialists, depending on the diagnosis. Cases may involve oncologists, hematologists, nephrologists, surgeons, regenerative medicine teams, or other specialty physicians.

This step is not a final treatment guarantee. It is a screening stage to understand medical suitability, urgency, risk, and possible treatment direction.

What You Receive

After review, patients may receive preliminary eligibility feedback, possible hospital options, an indicative treatment direction, estimated timeline, and rough cost range.

There is no obligation and no payment required at this stage.

Step 2 — Hospital and Specialist Matching

After the case review, ChinaCureLink matches the patient with suitable hospitals or specialists in China.

Matching is based on treatment specialization, hospital experience, technology access, trial availability, international patient support, language needs, city logistics, and urgency.

Related Guide:CAR-T Therapy in China: Cost, Timeline and Treatment AccessFor patients exploring advanced cancer treatment, this guide explains CAR-T therapy options, treatment timeline, risks, and cost considerations in China.→ https://www.chinacurelink.com/blog/car-t-therapy-in-china

Step 3 — Treatment Plan and Transparent Quote

Once a hospital or specialist pathway is identified, the next step is a treatment plan and quote.

What the Protocol Document Includes

The treatment plan may include the recommended hospital, specialist department, treatment type, expected tests after arrival, estimated length of stay, possible treatment schedule, recovery window, and follow-up requirements.

For complex cases, the plan may include alternative pathways. For example, a cancer patient may need another biopsy, molecular testing, bridging therapy, surgery review, or clinical trial screening before a final treatment decision.

Cost Breakdown Structure

A transparent quote should separate consultation fees, hospital testing, treatment fees, medication, hospitalization, interpreter support, local coordination, airport pickup, accommodation support, and possible extra costs.

This helps families avoid surprise billing.

Patients should also understand that the final cost may change after in-person evaluation if additional tests, complications, longer stay, or treatment changes are needed.

Related Cost Guides:

Add the relevant country-of-origin cost comparison page here:→https://www.chinacurelink.com/post/medical-tourism-to-china-the-complete-2026-guide-for-southeast-asian-patients

For kidney-related treatment planning, see:→ https://www.chinacurelink.com/post/blog-real-kidney-failure-patient-journey-china-case-study

Step 4 — Medical Visa, Travel and Arrival Logistics

After the treatment pathway is accepted, ChinaCureLink supports travel planning.

Medical Visa Support

Visa requirements depend on the patient’s nationality, destination city, length of stay, and local Chinese embassy or visa center rules. For medical travel, supporting documents may include a hospital invitation letter, appointment confirmation, proof of planned admission, travel itinerary, passport details, and caregiver documentation where required.

ChinaCureLink helps prepare hospital-side documents where available, but final visa approval is always decided by the relevant authority.

Flights, Pickup and Accommodation

The team may help coordinate flight timing, airport arrival, pickup, nearby hotel or serviced apartment options, and hospital appointment scheduling.

Patients are usually advised not to book flights too early, especially if the case requires hospital acceptance, visa approval, or medical clearance before travel.

Bringing a Companion

Many patients travel with a family member or caregiver. This is often helpful for communication, emotional support, medication management, mobility, and discharge planning.

For Gulf patients, direct routes to major Chinese cities may be available from hubs such as Dubai, Doha, Riyadh, Jeddah, or Abu Dhabi. For Southeast Asian patients, shorter regional flights may make China easier to access, depending on the departure city.

Step 5 — Admission and Treatment Phase

After arrival, patients usually undergo re-evaluation before treatment begins.

The First 48 Hours

Chinese hospitals commonly re-check key diagnostics after arrival. This may include blood tests, imaging, infection screening, cardiac assessment, kidney function testing, tumor markers, pathology review, or other baseline workup.

This protects the patient because medical status can change between remote review and arrival.

Daily Role of the Bilingual Patient Coordinator

A bilingual coordinator may help with appointment flow, translation, hospital navigation, daily schedule explanation, communication with family, discharge paperwork, and practical questions.

This role is important because patients are not only dealing with treatment. They are also navigating a new language, city, hospital system, and medical culture.

Typical Length of Stay by Treatment Type

Treatment Type	Typical Stay Range
CAR-T therapy	4–8 weeks, depending on manufacturing and monitoring
Stem cell therapy	1–3 weeks, depending on protocol and monitoring
Oncology surgery	2–6 weeks, depending on surgery and recovery
Nephrology evaluation	1–3 weeks, depending on testing and treatment
Advanced cancer consultation	Several days to 2 weeks

These are general ranges only. Final timing depends on the patient’s condition and hospital plan.

Step 6 — Discharge and Recovery in China

Discharge does not always mean the patient should fly home immediately.

Some treatments require a recovery window in China. For example, CAR-T patients may need monitoring for fever, infection, cytokine release syndrome, or neurologic symptoms. Surgery patients may need wound review, mobility support, and follow-up imaging. Kidney patients may need repeat labs, dialysis coordination, blood pressure monitoring, or symptom review.

During this stage, ChinaCureLink may help coordinate accommodation near the hospital, follow-up visits, translation of discharge documents, and communication with the care team.

The goal is to help the patient leave China safely, not quickly.

Step 7 — Follow-Up After You Return Home

This is where ChinaCureLink differs from “book and forget” medical facilitators.

After the patient returns home, follow-up may include remote consultations, translated medical records, lab review, imaging review, medication clarification, and coordination with the patient’s local physician.

For serious conditions, follow-up is not optional. Cancer patients may need ongoing scans and blood work. Kidney patients may need creatinine, eGFR, urine protein, blood pressure logs, dialysis planning, or nephrology follow-up.

The ChinaCureLink process is designed to support continuity of care so the patient is not left alone after discharge.

FAQ: Frequently Asked Questions

How long does the whole ChinaCureLink process take?

Many patients move from first inquiry to treatment start in about 3–6 weeks. Complex cases may take longer if more records, visa documents, hospital review, or medical stabilization are needed.

Is the case review really free?

Yes. The initial remote case review is free and no-obligation. Patients submit records first so the team can understand whether treatment in China may be reasonable.

Can my family come with me?

Yes. Many patients travel with a companion or caregiver. Family support can be very helpful during hospital visits, recovery, translation, meals, and emotional support.

What if I am not eligible?

If the patient is not eligible, the team should explain why. Some patients may need more testing, stabilization, local treatment, or a different medical pathway before travel is safe.

Do I pay ChinaCureLink or the hospital?

Payment structure depends on the treatment pathway and service agreement. Patients should request written details showing what is paid to the hospital, what is paid for coordination, and what is excluded.

Can ChinaCureLink help kidney failure patients?

Yes, selected kidney patients may be reviewed for treatment planning in China. Eligibility depends on CKD stage, dialysis status, infection risk, heart health, kidney function, and overall stability.

Related kidney case study:→https://www.chinacurelink.com/post/blog-real-kidney-failure-patient-journey-china-case-study

Start Your Free Case Review

Your path to medical treatment in China starts with one simple step: a free remote review of your medical records.

Most patients move from first inquiry to treatment start in about 3–6 weeks, depending on diagnosis, hospital review, visa timing, and travel readiness.

ChinaCureLink helps with case review, hospital matching, treatment planning, travel coordination, bilingual support, and follow-up after returning home.

Start your free case review today. No obligation. No payment at the review stage.

About ChinaCurelink

ChinaCurelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.

We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.

ChinaCurelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.

This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.